Soin Neuroscience commences a clinical case series with Nuvectra's Algovita spinal cord stimulator for back pain
DAYTON, Ohio, March 8, 2018 /PRNewswire/ -- Soin Neuroscience, a biotech company based in Dayton, OH, has received IRB (institutional review board) approval to commence a clinical case series to study spinal cord stimulator algorithms in patients who suffer from back pain. Dr Amol Soin, a pain management physician and CEO of Soin Neuroscience, will be running the study in Dayton, OH. "I look forward to using Nuvectra's Algovita, and its powerful spinal cord stimulator system to treat patients with back pain. We will be trialing waveforms that are unique to Nuvectra's system. This is a small study that I hope will allow us to run additional larger studies. I think we can help a lot of people with back pain."
The study will be run in Dayton, OH. Patients who suffer from debilitating back may be considered good candidates for the study.
About Soin Neuroscience:
Soin Neuroscience (SNI) is a pharmaceutical startup company based in Dayton, OH that specializes in treating pain and other neurological conditions. Its lead compound, TV1001SR, is entering late stage trials to treat systemic sclerosis and diabetic peripheral neuropathy. SNI also has multiple other compounds in development including a way to restore functional motor and cognitive function after ischemic stroke, a method to treat intensive care unit myopathy, and is working on an option to treat Huntington's disease. The company was founded by Dr. Amol Soin who is also an inventor on most of the core technologies that are being developed. He can be reached at firstname.lastname@example.org.